Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenotypeca neoantigen cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Phenotypeca
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Phenotypeca's neoantigen cancer vaccine is an immunotherapy candidate designed to elicit a targeted immune response against tumor-specific antigens. Leveraging Phenotypeca's proprietary *Saccharomyces cerevisiae* (yeast) strain engineering platform, the vaccine aims to produce and deliver patient-specific or tumor-specific neoantigens. The mechanism involves priming the immune system, particularly T-cells, to recognize these unique mutations on the surface of cancer cells, leading to selective destruction of the tumor while sparing healthy tissue. The vaccine is part of Phenotypeca's broader pipeline of yeast-expressed biologics and biosimilars.
- Other names
- Neoantigen cancer vaccinePhenotypeca tumor neoantigen vaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Phenotypeca neoantigen cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phenotypeca neoantigen cancer vaccine.